News

Zacks.com on MSN1mon
LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study
Baricitinib, a once-daily, oral JAK inhibitor, is already approved under the brand name Olumiant to treat adult patients with ...
Longview News-Journal1mon
Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
In 2022, the U.S. Food and Drug Administration (FDA) approved baricitinib (commercially available as Olumiant) for adult patients with severe AA, making it the first systemic treatment approved in ...
pharmaphorum2d
Lilly scores with two Olumiant trials in atopic dermatitis
Top-line data from the two studies of Olumiant (baricitinib) as a monotherapy in AD – BREEZE-AD1 and BREEZE-AD2 – show that the drug hit the main objective of achieving a significant ...
pharmaphorum5d
Lilly’s Olumiant is first JAK drug backed by NICE for eczema
Olumiant (baricitinib) has been backed by cost-effectiveness agency NICE to treat moderate to severe atopic dermatitis in adults who haven’t responded to or are ineligible for treatment with ...
Wane1mon
Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
Late-breaking results presented at AAD show 80% or more scalp hair coverage at Week 36 in 42.4% of adolescents receiving baricitinib 4 mg Patients treated with baricitinib 4 mg saw significant ...